XBiotech Inc. (XBIT) XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
XBiotech Inc. NASDAQ:XBIT Healthcare · Biotechnology
Mkt Cap $57.32M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 1
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
XBiotech's board elected Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers, effective Oct. 23, 2026.
Dr. Shivaswamy, a 17-year company veteran and CSO since 2017, had been interim CEO since December 2025 following founder John Simard's retirement; Jan-Paul Simard joined in 2012 and worked in clinical development across pancreatic cancer, NSCLC, osteoarthritis and rheumatoid arthritis trials.
Both are internal promotions with continuity of leadership, so the announcement formalizes rather than disrupts the management structure of the micro-cap biotech.
• 9d ago AI analysis › Press Release ● Major ⚠ 4
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
XBiotech announced positive final Phase II results from the investigator-sponsored TASKIN trial of vilamakitug (XB2001) plus TAS-102 in refractory metastatic colorectal cancer, meeting the pre-specified efficacy success criterion with 61.3% 12-month overall survival versus 55.7% in the control arm.
The exploratory subgroup analysis showed a statistically significant 62% reduction in risk of death (HR 0.38) and 61% reduction in treatment strategy failure (HR 0.39) in right-sided primary tumors, an aggressive high-need subtype.
Management says the biomarker-anchored right-sided population provides a validated direction as vilamakitug advances toward registrational development.
Note the ITT secondary endpoints (median PFS 5.9 vs 5.6 months, p=0.42) were not statistically significant, so the registrational case rests largely on the subgroup signal.
• 13d ago AI analysis › Press Release
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
XBiotech announced that the FDA completed its 30-day review of the IND application for the V-SPINE study without placing a clinical hold, clearing the path for U.S. patient enrollment.
The Phase II, double-blind, placebo-controlled trial will evaluate 400 mg of vilamakitug administered via 16 weekly subcutaneous injections in 150 adult participants with active axial spondyloarthritis.
The primary endpoint is the proportion of participants achieving an ASAS40 response at Week 16, with a 12-week open-label extension planned for all participants.
This milestone marks the resumption of XBiotech’s rheumatology program, leveraging its True Human™ antibody platform to target IL-1α, an upstream inflammatory mediator.
• 4mo ago AI analysis › 
